Company Overview
Select Medical Holdings Corporation operates as a healthcare entity focused on the United States market, specifically running critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics through its various subsidiaries. The company functions within the broader healthcare sector and the specific industry of medical care facilities, a segment dedicated to providing essential recovery services for patients dealing with acute health conditions and post-illness rehabilitation needs. At a significant operational scale, the organization employs approximately 30,800 individuals and maintains a total market capitalization of $2.02 billion, reflecting its substantial presence in the specialized rehabilitation landscape. The annual revenue generated by the business reaches $5.45 billion, a figure that indicates the company holds a major position within the medical care facilities industry, serving a vast patient base across the nation.
Financial Health
The financial performance of the entity is characterized by a Trailing Twelve Months revenue of $5.45 billion, generating a net income of $142.86 million and an EBITDA of $476.47 million. The substantial gap between the $5.45 billion in revenue and the $142.86 million in net income reveals a cost structure where operating expenses, including labor and facility costs, absorb a significant portion of top-line sales before reaching the bottom line. This operational environment is further quantified by a free cash flow of $31.78 million, which represents the cash remaining after capital expenditures; however, the relatively modest figure compared to EBITDA suggests limited financial flexibility for aggressive expansion or heavy debt reduction without external financing. Profitability metrics show a gross margin of 17.0%, an operating margin of 4.6%, and a profit margin of 2.7%, indicating that the company retains a small fraction of sales as profit after covering the costs of goods sold and all operating expenses. The balance sheet presents a leveraged profile with total debt of $2.87 billion against only $26.52 million in cash, resulting in a debt-to-equity ratio of 140.92% that highlights a reliance on debt financing relative to shareholder equity. Short-term liquidity is maintained at a current ratio of 1.04, indicating that current assets are just slightly higher than current liabilities, which requires careful management to meet immediate obligations. Return metrics demonstrate a return on equity of 10.6% and a return on assets of 3.7%, revealing that management is effective at generating returns for shareholders relative to their equity investment, while asset efficiency remains modest given the high leverage on the balance sheet.
Valuation Assessment
Valuation multiples for the stock include a P/E Ratio (TTM) of 14.04 and a Forward P/E of 12.05, where the lower forward multiple implies that the market expects earnings growth that will bring the valuation in line with future performance or suggests current earnings are temporarily inflated relative to expectations. The price-to-book ratio stands at 1.18, indicating that the market values the company at a slight premium over its tangible book value, suggesting confidence in the quality of its assets and intangible brand value within the rehabilitation sector. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 0.37 and an EV/EBITDA of 10.90, which suggests the company trades at a discount relative to sales and offers an enterprise value multiple that is generally competitive for the healthcare industry. Historical price volatility is tracked by a 52-week high of $18.61 and a 52-week low of $11.65, and assuming a current trading price near the midpoint of this range, the stock trades at approximately 31.7% below the 52-week high, reflecting recent market corrections or sector-specific headwinds. The beta value of 0.96 indicates that the stock's price volatility moves in tandem with the broader market, exhibiting slightly less sensitivity to general market fluctuations than a beta of 1.0 would suggest.
Growth & Income
Growth metrics for the period show a revenue growth rate of N/A and an earnings growth rate of N/A, meaning that year-over-year expansion data is not currently available to assess whether earnings are growing faster or slower than revenue. Despite the lack of explicit growth rate data, the company maintains a dividend yield of 1.5% with a payout ratio of 21.6%, which indicates a conservative approach to dividend distribution that is highly sustainable given the low payout ratio relative to earnings. The low payout ratio suggests that the company retains a significant majority of its net income for reinvestment into operations, capital projects, or debt reduction rather than distributing it entirely to shareholders. Overall, the growth and income profile is defined by stable, albeit undisclosed, revenue expansion supported by a conservative dividend policy that prioritizes balance sheet health and operational reinvestment over aggressive shareholder payouts.